A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
← catalyst calendarNCT05605782 · readout in 2,533 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
9,000actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-02 | actual | When the study began enrolling |
| Primary completion | 2033-07-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-07-26 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis, Relapsing-Remitting
Primary outcomes
what the primary-completion date above is the date OFIncidence of major adverse cardiovascular events (MACE)
measured Up to 10 years
Incidence of serious opportunistic infection (SOI)
measured Up to 10 years
Incidence of serious acute liver injury (SALI)
measured Up to 10 years
Incidence of macular edema
measured Up to 10 years
Identified rate of malignancies identified based upon the presence of at least 1 international classification of diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code
measured Up to approximately 2 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed